Jenburkt Pharmaceuticals Share News - Latest Updates, Live News & More

Latest news about Jenburkt Pharmaceuticals

Jenburkt Pharma AGM passes resolutions with 99.99% shareholder support 9 days ago

Jenburkt Pharma AGM passed all resolutions with 99.99% support. Dilip H. Bhuta re-appointed as CFO for five years effective April 2027. Dividend of ₹20.70 per share (207%) declared for FY26. Promoters voted 19.16 lakh shares; public participation was low at 0.42%. No adverse qualifications in statutory or secretarial audit reports.

Jenburkt Pharmaceuticals elevates Prem Ashish Bhuta to AVP role 10 days ago

Jenburkt Pharmaceuticals Q1FY27 net profit falls 24% to ₹5.89 crore Aug 07, 2026

Jenburkt Pharmaceuticals sets Sep 4 for 41st AGM Aug 04, 2026

Jenburkt Pharmaceuticals posts 8.3% profit rise in FY26, recommends ₹20.70 dividend Aug 03, 2026

More news about Jenburkt Pharmaceuticals

18Jun 26

Jenburkt Pharmaceuticals closes trading window ahead of Q1FY27 results

Jenburkt Pharmaceuticals Ltd has closed its trading window from July 1, 2026, for designated persons and insiders. The window will reopen 48 hours after the Q1FY27 standalone unaudited financial results are made public. The board meeting schedule for the results will be announced later.

06May 26

Jenburkt Pharmaceuticals Publishes Standalone Audited Financial Results for Quarter and FY26 Ended March 31, 2026

Jenburkt Pharmaceuticals Limited published its standalone audited financial results for the quarter and financial year ended March 31, 2026, following Board approval on May 5, 2026. The results were disclosed in The Free Press Journal (English) and Navshakti (Marathi) on May 6, 2026, in compliance with Regulation 33 read with Regulation 47(1) of the SEBI (LODR) Regulations, 2015. The full financial results are accessible on the BSE India website and the company's investor relations portal. The filing was authorised by Chairman & Managing Director Ashish U. Bhuta (DIN: 00226479) and submitted by Company Secretary Ashish R. Shah.

14Apr 26

Jenburkt Pharmaceuticals confirms 'not a large corporate' status for FY26

Jenburkt Pharmaceuticals Limited disclosed to BSE Limited on April 14, 2026, that it maintains 'not a large corporate' status for FY ended March 31, 2026. The disclosure complies with SEBI Circular SEBI/HO/DDHS/CIR/2021/613, confirming the company does not meet large corporate criteria under Clause 2.1 of Chapter XII. The communication was jointly authorized by Whole Time Director & CFO Dilip H. Bhuta and Sr. Vice President & Company Secretary Ashish R. Shah.

07Apr 26

Jenburkt Pharmaceuticals Files Quarterly Compliance Certificate for Q4 FY26

Jenburkt Pharmaceuticals Ltd has submitted its quarterly compliance certificate to BSE Ltd for Q4 FY26 ended March 31, 2026. The certificate, issued by registrar Bigshare Services Pvt. Ltd., confirms compliance with SEBI Regulation 74(5) regarding dematerialization processes. The filing demonstrates the company's adherence to regulatory requirements and proper handling of securities transactions during the quarter.

03Feb 26

Jenburkt Pharmaceuticals Reports Q3FY26 Results with Revenue of Rs 4302.39 Lacs

Jenburkt Pharmaceuticals reported Q3FY26 revenue from operations of Rs 4302.39 lacs, up 16.63% year-over-year but down from Rs 4555.76 lacs in Q2FY26. Net profit declined to Rs 593.14 lacs from Rs 650.75 lacs in Q3FY25. Nine-month performance showed revenue growth of 12.17% to Rs 12410.83 lacs and net profit increase of 1.54% to Rs 2388.66 lacs. The results were approved by the Board on February 3, 2026.

28Oct 25

Jenburkt Pharmaceuticals Reports 10.5% Revenue Growth in Q2 FY2026

Jenburkt Pharmaceuticals Limited announced strong Q2 FY2026 results. Revenue from operations increased by 10.5% to Rs 4,555.70 lacs, while profit after tax grew by 11.3% to Rs 1,133.20 lacs compared to Q2 FY2025. Total income rose by 10.6% to Rs 4,763.66 lacs. For the half-year ended September 30, 2025, total revenue reached Rs 8,108.40 lacs, a 10% increase from the previous year. The company continues to focus exclusively on the pharmaceuticals segment. The Board of Directors approved these unaudited financial results on October 28, 2025, following a limited audit review by D.R. Mehta & Associates.

20May 25

Jenburkt Pharmaceuticals Reports Strong Q4 Results, Announces Dividend

Jenburkt Pharmaceuticals released its Q4 financial results, showing significant growth. Revenue increased by 5.80% to ₹410.50 crore. EBITDA rose by 10.25% to ₹108.60 crore, with the EBITDA margin expanding to 26.45%. Net profit grew by 8.10% to ₹85.40 crore. The company also announced a dividend of ₹18.00 per equity share.

Jenburkt Pharmaceuticals

1,003.90

-22.90

(-2.23%)

1 Year Returns:0.00%

Industry Peers

Sun Pharmaceutical

1,840.00

(-1.13%)

Divis Laboratories

9,322.00

(-1.23%)

Torrent Pharmaceuticals

4,965.50

(+0.72%)

Zydus Life Science

1,119.10

(+0.12%)

Cipla

1,366.00

(-0.53%)

Laurus Labs

1,969.00

(+1.23%)

Dr Reddys Laboratories

1,165.50

(+1.97%)

Aurobindo Pharma

1,679.80

(+0.68%)

Lupin

2,095.00

(+0.83%)

Mankind Pharma

2,280.00

(+1.86%)

Get More Market Insights with

Stock Rental via SLBM

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104